Literature DB >> 9773047

[Autosomal dominant nocturnal frontal lobe epilepsy].

P Thomas1, F Picard, E Hirsch, M Chatel, C Marescaux.   

Abstract

Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a recently identified seizure disorder. The disease maps to the long arm of chromosome 20 and may be related in some families to a missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit. We describe one of the first European family with ADNFLE, including five affected individuals spanning four generations. In the most severely affected subject, the onset was during the second month of life and persisted through adult life. Seizures were very frequent during infancy, although long-term evolution was relatively benign. Ictal video-EEG studies showed that attacks occurred in clusters during sleep and were partial seizures that were consistent with a frontal origin. Neuro-imaging was normal. Carbamazepine had a dramatic effectiveness. Although recognition of this syndrome is important for appropriate therapy and genetic counselling, underestimation of cases is likely: the disease was in our family perceived like a hereditary curse, and subsequently concealed, including to medical attention. Relationships with other partial familial epilepsies and with idiopathic benign partial epilepsies of childhood are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773047

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  2 in total

1.  Mutations of DEPDC5 cause autosomal dominant focal epilepsies.

Authors:  Saeko Ishida; Fabienne Picard; Gabrielle Rudolf; Eric Noé; Guillaume Achaz; Pierre Thomas; Pierre Genton; Emeline Mundwiller; Markus Wolff; Christian Marescaux; Richard Miles; Michel Baulac; Edouard Hirsch; Eric Leguern; Stéphanie Baulac
Journal:  Nat Genet       Date:  2013-03-31       Impact factor: 38.330

2.  Nocturnal Frontal Lobe Epilepsy vs Parasomnias.

Authors:  Christopher Derry
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.